Literature DB >> 9241302

Differences in the estrogen content of breast adipose tissue in women by menopausal status and hormone use.

S N O'Brien1, J Anandjiwala, T M Price.   

Abstract

OBJECTIVE: To determine the levels of free estrone (E1) and estradiol (E2) in breast adipocytes of premenopausal women, premenopausal women using oral contraceptives (OCs), postmenopausal women, and postmenopausal women using estrogen replacement therapy (ERT).
METHODS: Breast adipose tissue was obtained from 36 premenopausal and 29 postmenopausal women, and adipocytes were separated from stromal and epithelial cells through collagenase digestion and centrifugation. Oil was rendered from adipocytes, and E1 and E2 levels were measured by specific radioimmunoassays after extraction with methanol-water.
RESULTS: Estrone and E2 levels were approximately 2.4- and 7.8-fold higher, respectively, in premenopausal women than in postmenopausal women. In premenopausal women, E1 and E2 correlated with the time since last menses (R2 = .55 and .62, respectively), whereas in postmenopausal women, E1 and E2 correlated with body mass index (BMI) (r = .48 and .52, respectively). Estrone levels were always greater than E2 levels in adipocytes, with the E1/E2 ratio being 2.7-fold higher in postmenopausal women than in premenopausal women. The use of OCs decreased E1 and E2 levels in premenopausal women, and ERT increased levels in postmenopausal women.
CONCLUSION: Free estrogen in breast adipocytes is characterized by E1 dominance, with levels in premenopausal women correlating with the menstrual cycle and levels in postmenopausal women correlating with BMI.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241302     DOI: 10.1016/S0029-7844(97)00212-3

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

Review 1.  Clinical opinion: the biologic and pharmacologic principles for age-adjusted long-term estrogen therapy.

Authors:  Morris Notelovitz
Journal:  MedGenMed       Date:  2006-03-28

Review 2.  Estrogens in the breast tissue: a systematic review.

Authors:  Lusine Yaghjyan; Graham A Colditz
Journal:  Cancer Causes Control       Date:  2011-02-01       Impact factor: 2.506

3.  Disposition of hop prenylflavonoids in human breast tissue.

Authors:  Selin Bolca; Jinghu Li; Dejan Nikolic; Nathalie Roche; Phillip Blondeel; Sam Possemiers; Denis De Keukeleire; Marc Bracke; Arne Heyerick; Richard B van Breemen; Herman Depypere
Journal:  Mol Nutr Food Res       Date:  2010-07       Impact factor: 5.914

Review 4.  Postmenopausal tibolone therapy: biologic principles and applied clinical practice.

Authors:  Morris Notelovitz
Journal:  MedGenMed       Date:  2007-01-03

5.  Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study.

Authors:  Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2010-05-25       Impact factor: 2.506

6.  Measurement of sex steroid hormones in breast adipocytes: methods and implications.

Authors:  Roni T Falk; Elisabet Gentzschein; Frank Z Stanczyk; Louise A Brinton; Montserrat Garcia-Closas; Olga B Ioffe; Mark E Sherman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

7.  Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.

Authors:  Yujing J Heng; Jun Wang; Thomas U Ahearn; Susan B Brown; Xuehong Zhang; Christine B Ambrosone; Victor Piana de Andrade; Adam M Brufsky; Fergus J Couch; Tari A King; Francesmary Modugno; Celine M Vachon; Natalie C DuPre; Montserrat Garcia-Closas; Melissa A Troester; David J Hunter; A Heather Eliassen; Rulla M Tamimi; Susan E Hankinson; Andrew H Beck
Journal:  Breast Cancer Res Treat       Date:  2018-11-01       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.